Last 48 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has expanded 38.1% YoY to 55.1x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -2.01 | — | — | — | — | — | 22.68 | — | — | — | 43.55 | 39.78 | 199.27 |
| — | — | — | — | — | — | -47.9% | — | — | — | +95.7% | +125.4% | +696.7% | |
| P/S Ratio | 0.65 | 0.46 | 0.55 | 0.68 | 0.56 | 1.10 | 0.99 | 0.91 | 1.35 | 1.87 | 2.15 | 1.99 | 2.19 |
| — | -57.9% | -44.5% | -25.0% | -58.2% | -41.2% | -54.1% | -54.2% | -38.4% | -39.8% | -27.1% | -13.1% | -22.9% | |
| P/B Ratio | 1.00 | 0.70 | 0.91 | 1.06 | 0.90 | 1.10 | 1.13 | 0.91 | 1.47 | 1.72 | 2.15 | 1.93 | 1.98 |
| — | -37.0% | -19.2% | +16.1% | -38.6% | -36.0% | -47.4% | -52.7% | -25.9% | -38.9% | -17.4% | -5.8% | -27.1% | |
| P/FCF | — | — | — | 10.68 | — | — | 39.03 | — | 52.73 | 2367.44 | 24.92 | 55.65 | 65.54 |
| — | — | — | — | — | — | +56.6% | — | -19.5% | +2395.0% | +50.7% | +272.8% | +231.2% | |
| EV / EBITDA | 13.01 | 55.09 | 1.16 | 9.16 | — | 39.89 | 11.91 | 28.44 | 30.00 | 30.45 | 17.96 | 19.53 | 26.72 |
| — | +38.1% | -90.3% | -67.8% | — | +31.0% | -33.7% | +45.6% | +12.3% | +38.9% | +19.3% | +58.2% | +67.5% | |
| EV / EBIT | 41.77 | — | 24.58 | 45.18 | — | — | 20.98 | — | 292.12 | 125.27 | 28.26 | 35.23 | 71.09 |
| — | — | +17.2% | — | — | — | -25.8% | — | +310.9% | +248.0% | +43.9% | +112.5% | +212.9% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Integra LifeSciences Holdings Corporation's operating margin was 2.9% in Q1 2026, down 125.0 pp QoQ and up 7.0 pp YoY. The trailing four-quarter average of 4.4% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 51.7% | — | 49.5% | 56.2% | 50.4% | 50.8% | 56.3% | 52.6% | 54.0% | 56.1% | 57.0% | 57.1% | 54.3% |
| — | — | -12.0% | +7.0% | -6.8% | -9.4% | -1.4% | -7.9% | -0.5% | -8.3% | -9.2% | -7.1% | -13.4% | |
| Operating Margin | 4.2% | 2.9% | 127.9% | 10.0% | -123.4% | -4.0% | 8.0% | -2.1% | -0.7% | 1.1% | 9.1% | 7.0% | 3.3% |
| — | +172.3% | +1488.9% | +568.3% | -16931.1% | -476.9% | -11.3% | -130.8% | -122.1% | -88.8% | -46.7% | -58.8% | -78.2% | |
| Net Margin | -31.6% | -1.2% | -0.4% | -1.3% | -116.5% | -6.6% | 4.4% | -2.8% | -3.0% | -0.9% | 5.0% | 5.1% | 1.1% |
| — | +82.2% | -108.9% | +52.1% | -3827.4% | -643.1% | -12.1% | -155.1% | -370.2% | -114.0% | -62.4% | -60.7% | -90.3% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -39.9% | -0.4% | -0.2% | -0.5% | -37.8% | -1.6% | 1.3% | -0.7% | -0.8% | -0.2% | 1.3% | 1.2% | 0.2% |
| — | +73.1% | -112.9% | +25.6% | -4670.4% | -700.0% | +1.2% | -158.6% | -417.8% | -114.8% | -58.3% | -59.5% | -90.9% | |
| ROA | -13.5% | -0.1% | -0.0% | -0.1% | -12.5% | -0.6% | 0.5% | -0.3% | -0.3% | -0.1% | 0.5% | 0.5% | 0.1% |
| — | +79.4% | -109.8% | +43.8% | -4022.2% | -648.9% | -9.0% | -150.7% | -373.3% | -113.2% | -61.7% | -60.7% | -90.8% | |
| ROIC | 1.7% | 0.3% | 14.8% | 1.1% | -12.5% | -0.4% | 0.8% | -0.2% | -0.1% | 0.1% | 0.9% | 0.7% | 0.3% |
| — | +185.7% | +1717.2% | +680.2% | -17495.1% | -458.6% | -10.1% | -127.6% | -122.6% | -89.3% | -47.5% | -59.7% | -79.6% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Integra LifeSciences Holdings Corporation's Debt/EBITDA ratio is 177.8x, up from 3.4x last quarter — elevated, raising questions about debt serviceability. The current ratio has improved 180.3% YoY to 3.38x, strengthening the short-term liquidity position. Debt/Equity has risen for 3 consecutive quarters, indicating increasing financial leverage that investors should watch closely.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.95 | 1.96 | 1.95 | 1.93 | 1.94 | 1.32 | 1.28 | 1.31 | 1.31 | 1.28 | 1.06 | 1.07 | 0.95 |
| — | +47.7% | +51.7% | +47.9% | +48.0% | +3.6% | +21.3% | +22.2% | +37.5% | +32.9% | +17.2% | +6.8% | -8.5% | |
| Debt / EBITDA | 9.27 | 177.81 | 3.42 | 25.57 | — | 93.08 | 27.14 | 71.53 | 59.54 | 59.15 | 25.09 | 29.56 | 37.00 |
| — | +91.0% | -87.4% | -64.3% | — | +57.4% | +8.2% | +142.0% | +60.9% | +152.5% | +49.8% | +64.5% | +94.6% | |
| Current Ratio | 2.54 | 3.38 | 2.54 | 3.14 | 1.23 | 1.21 | 1.17 | 1.20 | 3.39 | 4.68 | 3.45 | 2.89 | 2.78 |
| — | +180.3% | +116.8% | +160.7% | -63.7% | -74.2% | -66.0% | -58.3% | +21.7% | +28.4% | -4.8% | -26.5% | -27.6% | |
| Quick Ratio | 1.46 | 1.95 | 1.46 | 1.80 | 0.73 | 0.72 | 0.71 | 0.73 | 2.10 | 3.35 | 2.18 | 1.86 | 1.85 |
| — | +170.9% | +106.6% | +147.6% | -65.3% | -78.5% | -67.5% | -60.9% | +13.9% | +39.3% | -16.5% | -36.1% | -33.2% | |
| Interest Coverage | -5.53 | 0.51 | 1.18 | 0.70 | -24.23 | -0.55 | 2.19 | -0.05 | 0.19 | 0.62 | 3.10 | 2.42 | 1.31 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorDCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare business quality, growth, and profitability against top sector peers.
Start ComparisonQuick answers to the most common questions about buying IART stock.
Integra LifeSciences Holdings Corporation's current P/E is -2.0x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Integra LifeSciences Holdings Corporation's current operating margin is 4.2%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Integra LifeSciences Holdings Corporation's business trajectory between earnings reports.